Kaiyan Yang
Impact in
- Cancer Research top 5%
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
- Breast Cancer Treatment Studies
-
- CAR-T cell therapy research
Papers in
-
- MicroRNA in disease regulation 4
- Carcinogens and Genotoxicity Assessment 2
- Oncology 5
- CAR-T cell therapy research 2
- Co-authors
- Xiaorong Li (8 shared papers)Gui Ming Hu (6 shared papers)Wei Wu (1 shared paper)Daojin Chen (1 shared paper)Hongxian Wang (1 shared paper)Changwei Lin (6 shared papers)Haihua Gu (5 shared papers)Fei Long (4 shared papers)
- Journals
- Cancers (2 papers)BMC Cancer (1 paper)Frontiers in Oncology (1 paper)Cell Death and Disease (1 paper)Gut (1 paper)
- Partner nations
- ChinaUnited StatesAustralia
In The Last Decade
Kaiyan Yang
38 papers receiving 770 citations
Peers
Comparison fields: 5 of 59
- Cancer Research 258
- Oncology 125
- Pulmonary and Respiratory Medicine 110
- Molecular Biology 184
- Virology 11
Countries citing papers authored by Kaiyan Yang
This map shows the geographic impact of Kaiyan Yang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kaiyan Yang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kaiyan Yang more than expected).
Fields of papers citing papers by Kaiyan Yang
This network shows the impact of papers produced by Kaiyan Yang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kaiyan Yang. The network helps show where Kaiyan Yang may publish in the future.
Co-authors
The 25 scholars most cited alongside Kaiyan Yang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 39 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2022 | 116 | |
| 2 | 2010 | 107 | |
| 3 | 2022 | 59 | |
| 4 | 2017 | 56 | |
| 5 | 2020 | 40 | |
| 6 | Overcome trastuzumab resistance of breast cancer using anti-HER2 chimeric antigen receptor T cells and PD1 blockade. | 2020 | 34 |
| 7 | 2007 | 33 | |
| 8 | 2014 | 28 | |
| 9 | 2020 | 26 | |
| 10 | 2021 | 25 | |
| 11 | 2009 | 21 | |
| 12 | 2014 | 19 | |
| 13 | 2011 | 18 | |
| 14 | 2016 | 16 | |
| 15 | 2019 | 16 | |
| 16 | 2004 | 15 | |
| 17 | 2007 | 15 | |
| 18 | [Expression of microRNA-21 in invasive ductal carcinoma of the breast and its association with phosphatase and tensin homolog deleted from chromosome expression and clinicopathologic features]. | 2008 | 15 |
| 19 | 2018 | 14 | |
| 20 | 2007 | 13 |
About Kaiyan Yang
Kaiyan Yang is a scholar working on Cancer Research, Oncology, Pathology and Forensic Medicine, Pulmonary and Respiratory Medicine and Biochemistry, having authored 39 papers that have together received 792 indexed citations. Recurring topics across this work include MicroRNA in disease regulation (4 papers), Lymphoma Diagnosis and Treatment (4 papers), Mitochondrial Function and Pathology (2 papers), CAR-T cell therapy research (2 papers), Ferroptosis and cancer prognosis (2 papers), Lipid metabolism and biosynthesis (2 papers), Immunotoxicology and immune responses (2 papers) and Carcinogens and Genotoxicity Assessment (2 papers). The work is most often cited by research in Cancer Research (258 citations), Oncology (125 citations), Pulmonary and Respiratory Medicine (110 citations), Molecular Biology (184 citations) and Virology (11 citations). Kaiyan Yang has collaborated with scholars based in China, United States and Australia. Frequent co-authors include Xiaorong Li, Gui Ming Hu, Wei Wu, Daojin Chen, Hongxian Wang, Changwei Lin, Haihua Gu, Fei Long, Hongzhi Li and Zhixing Lu. Their work appears in journals such as Cancers, BMC Cancer, Frontiers in Oncology, Cell Death and Disease and Gut.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.